BiotechTube

MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months

Phase 2Completed
1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cutaneous T-cell Lymphoma

Conditions

Cutaneous T-cell Lymphoma, Sezary Syndrome, Mycosis Fungoides

Trial Timeline

Feb 3, 2005 → Mar 13, 2006

NCT ID
NCT00091559

About MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months

MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months is a phase 2 stage product being developed by Merck for Cutaneous T-cell Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00091559. Target conditions include Cutaneous T-cell Lymphoma, Sezary Syndrome, Mycosis Fungoides.

What happened to similar drugs?

7 of 20 similar drugs in Cutaneous T-cell Lymphoma were approved

Approved (7) Terminated (1) Active (12)
✅ONTAK (denileukin difitox, DAB389IL-2)EisaiApproved
✅ONTAKEisaiApproved
✅ONTAKEisaiApproved
✅MogamulizumabKyowa KirinApproved
✅Clopidogrel + TicagrelorAstraZenecaApproved
✅Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL + Normal Saline (Placebo)NovartisApproved
✅BexaroteneBausch HealthApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT00097929Phase 2Completed
NCT00091559Phase 2Completed

Competing Products

20 competing products in Cutaneous T-cell Lymphoma

See all competitors
ProductCompanyStageHype Score
ONTAK (denileukin difitox, DAB389IL-2)EisaiApproved
43
ONTAKEisaiApproved
43
E7777 9 mcg/kgEisaiPhase 3
40
ONTAKEisaiApproved
43
MogamulizumabKyowa KirinApproved
47
Mogamulizumab + Brentuximab vedotinKyowa KirinPhase 1
36
MogamulizumabKyowa KirinPhase 2
39
KW-0761 + VorinostatKyowa KirinPhase 3
40
EnzastaurinEli LillyPhase 2
35
Clopidogrel + TicagrelorAstraZenecaApproved
43
PembrolizumabMerckPhase 2
42
Comparator: vorinostatMerckPre-clinical
26
PembrolizumabMerckPhase 2
39
TR701 FAMerckPhase 2
35
PembrolizumabMerckPhase 2
42
Tulisokibart + PlaceboMerckPhase 2
39
Aspirin + Ipilimumab + PembrolizumabMerckPhase 2
35
Pembrolizumab + MogamulizumabMerckPhase 2
42
TR-701 FA + LinezolidMerckPhase 3
40
Pimasertib + DacarbazineMerckPhase 2
35